Status and phase
Conditions
Treatments
About
Study designed to evaluate the safety and efficacy of double staining with brilliant blue G 0.025% as an adjuvant to macular surgery. Patients undergoing surgery for macular hole or epiretinal membrane will be included. Safety will be evaluated by optic coherence tomography, pattern reversal electroretinogram and multifocal electroretinogram.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Exclusion criteria
Primary purpose
Allocation
Interventional model
Masking
22 participants in 1 patient group
Loading...
Central trial contact
Gerardo Garcia-Aguirre, MD; Hugo Sepúlveda-Vázquez, MD
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal